On January 17, 2020, the Centers for Medicare & Medicaid Services (CMS) issued additional guidance and clarification on four topics related to CY2021 requirements for Dual Eligible Special Needs Plans (D-SNPs). The guidance follows on an October 2019 an HPMS memo summarizing the new D-SNP requirements and providing guidance on contract and operational changes needed for CY2021.
On December 16, 2019, ICRC hosted a Study Hall Call on “Key Questions and Considerations for States Implementing New D-SNP Information-Sharing Requirements” that provided an update on new information-sharing requirements for Dual Eligible Special Needs Plans (D-SNPs) for 2021 and a review of key questions and considerations for states in working with D-SNPs to modify state contracts and develop a state-specific information-sharing approach.
November 2019 Contents:
On September 12, 2019, the Centers for Medicare & Medicaid Services (CMS) released the draft Contract Year 2021 Medicare Advantage-Prescription Drug Application for a 60-day public comment period. The draft MA-PD application shows how CMS proposes to collect information from Dual Eligible Special Needs Plans (D-SNPs) to verify that the plans will meet the new Medicaid integration requirements from the Bipartisan Budget Act of 2018 as codified in the April 2019 final rule (CMS-4185-F).
On April 5, 2019, the Centers for Medicare & Medicaid Services (CMS) published new final rule for Medicare Advantage and Part D that implements provisions of the Bipartisan Budget Act of 2018 related to the integration of Medicare and Medicaid services and unification of Medicare and Medicaid grievance and appeals procedures by Dual Eligible Special Needs Plans (D-SNPs).
On April 1, 2019, the Centers for Medicare & Medicaid Services (CMS) published the Final Call Letter and Rate Announcement outlining guidance for the 2020 plan year for Medicare Advantage (MA) plans, including Dual Eligible Special Needs Plans (D-SNPs) and Medicare-Medicaid Plans (MMPs) under the Financial Alignment Initiative.
